• Cryptocurrencies
  • Voorspellingsmarkten
  • Nieuws
  • Agentisch Handelen
  • Artikelen
  • Competities

Zoeken Cryptocurrencies

Trends Cryptocurrencies

CoinRithm

Bedrijf

Rechtspersoon
Bees-x Limited
Bedrijfsnummer
13308136
Opgericht in
England and Wales
Statutaire zetel
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm is een informatie- en onderzoeksdienst van Bees-x Limited. Het is niet door de Financial Conduct Authority (FCA) gemachtigd om gereguleerde activiteiten uit te voeren, en niets op deze site vormt financieel advies.

Ontdekken

CryptocurrenciesVoorspellingsmarktenNieuwsArtikelenAgent ArenaCompetities

Functies

DashboardNephandelAgentisch HandelenPortefeuilleVolglijstInstellingen

Bedrijf

Over OnsMethodologieGebruiks- voorwaardenPrivacybeleidCookiebeleidVrijwaring

Ondersteuning

KlantenserviceFAQOntwikkelaarskitMCP-documentatie

Sociale Media

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Rechten voorbehouden.
Verkrijgbaar via Google PlayDownloaden in de App Store
  • Home
  • MarktenVoorspellingsmarkten
  • Nieuws
  • Dashboard
  1. Voorspellingsmarkten
  2. Health & Medicine
  3. What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold Markets

What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?

Health & MedicineOne-Off2mnd
Manifold MarketsManifold MarketsGeen KYC
Huidige gemeenschapsvoorspelling
Manifold Markets
20-29% 9.4%
Koploper van 7 uitkomsten
Voorspellers

11

Vraagtype

multiple choice

Methodologie

Play-money forecasting platform

Brontype

Voorspelling

Marktdata

Bijgewerkt eergisteren

Verouderd
15 mrt 24, 21:292 sep 26, 6:59

Trends

Uitkomst24uKans

Gekozen uitkomst

20-29%9%

Regels

The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.

Manifold Markets
  • Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
  • Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2026).
  • Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
  • 1Day Sooner has an R21 Status Report available here that may be useful.
  • More malaria-related questions can be found on our Manifold account here.

Gerelateerde Markten

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

€ 145,3K
Ja: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

€ 16,6K
Ja: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

€ 8,7K
Ja: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

€ 1,3K
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

€ 462,5
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

€ 137,8
2025: 0%Manifold MarketsMANIFOLD MARKETS

Actief in deze onderwerpen

BitcoinBTC$62,928.32+2.44%EthereumETH$1,659.49+1.68%SolanaSOL$65.34+1.62%DogecoinDOGE$0.085+1.53%XRPXRP$1.12+0.39%BNBBNB$596.89+1.78%

Gerelateerd Nieuws

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Regels

The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.

Manifold Markets
  • Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
  • Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2026).
  • Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
  • 1Day Sooner has an R21 Status Report available here that may be useful.
  • More malaria-related questions can be found on our Manifold account here.